169 related articles for article (PubMed ID: 36534236)
41. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.
Brozos-Vázquez EM; Díaz-Peña R; García-González J; León-Mateos L; Mondelo-Macía P; Peña-Chilet M; López-López R
Cancer Immunol Immunother; 2021 May; 70(5):1177-1188. PubMed ID: 33113004
[TBL] [Abstract][Full Text] [Related]
42. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Theelen WSME; Chen D; Verma V; Hobbs BP; Peulen HMU; Aerts JGJV; Bahce I; Niemeijer ALN; Chang JY; de Groot PM; Nguyen QN; Comeaux NI; Simon GR; Skoulidis F; Lin SH; He K; Patel R; Heymach J; Baas P; Welsh JW
Lancet Respir Med; 2021 May; 9(5):467-475. PubMed ID: 33096027
[TBL] [Abstract][Full Text] [Related]
43. Combination therapy: Future directions of immunotherapy in small cell lung cancer.
Huang W; Chen JJ; Xing R; Zeng YC
Transl Oncol; 2021 Jan; 14(1):100889. PubMed ID: 33065386
[TBL] [Abstract][Full Text] [Related]
44. Emerging immunotherapy targets in lung cancer.
Zhu HH; Feng Y; Hu XS
Chin Med J (Engl); 2020 Oct; 133(20):2456-2465. PubMed ID: 32947361
[TBL] [Abstract][Full Text] [Related]
45. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
[TBL] [Abstract][Full Text] [Related]
46. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
Sholl LM; Hirsch FR; Hwang D; Botling J; Lopez-Rios F; Bubendorf L; Mino-Kenudson M; Roden AC; Beasley MB; Borczuk A; Brambilla E; Chen G; Chou TY; Chung JH; Cooper WA; Dacic S; Lantuejoul S; Jain D; Lin D; Minami Y; Moreira A; Nicholson AG; Noguchi M; Papotti M; Pelosi G; Poleri C; Rekhtman N; Tsao MS; Thunnissen E; Travis W; Yatabe Y; Yoshida A; Daigneault JB; Zehir A; Peters S; Wistuba II; Kerr KM; Longshore JW
J Thorac Oncol; 2020 Sep; 15(9):1409-1424. PubMed ID: 32522712
[TBL] [Abstract][Full Text] [Related]
47. Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
Reck M; Wehler T; Orlandi F; Nogami N; Barone C; Moro-Sibilot D; Shtivelband M; González Larriba JL; Rothenstein J; Früh M; Yu W; Deng Y; Coleman S; Shankar G; Patel H; Kelsch C; Lee A; Piault E; Socinski MA
J Clin Oncol; 2020 Aug; 38(22):2530-2542. PubMed ID: 32459597
[TBL] [Abstract][Full Text] [Related]
48. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
49. Combining Immunotherapy and Chemotherapy for Non-Small Cell Lung Cancer.
Judd J; Borghaei H
Thorac Surg Clin; 2020 May; 30(2):199-206. PubMed ID: 32327178
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
51. Advances and challenges in immunotherapy of small cell lung cancer.
Guo H; Li L; Cui J
Chin J Cancer Res; 2020 Feb; 32(1):115-128. PubMed ID: 32194311
[TBL] [Abstract][Full Text] [Related]
52. Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.
Carbone C; Piro G; Di Noia V; D'Argento E; Vita E; Ferrara MG; Pilotto S; Milella M; Cammarota G; Gasbarrini A; Tortora G; Bria E
Mediators Inflamm; 2019; 2019():7652014. PubMed ID: 31827379
[TBL] [Abstract][Full Text] [Related]
53. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer.
Liang H; Wang M
Cancer Manag Res; 2019; 11():7707-7719. PubMed ID: 31616186
[TBL] [Abstract][Full Text] [Related]
54. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
55. Natural product-based nanoformulations for cancer therapy: Opportunities and challenges.
Kashyap D; Tuli HS; Yerer MB; Sharma A; Sak K; Srivastava S; Pandey A; Garg VK; Sethi G; Bishayee A
Semin Cancer Biol; 2021 Feb; 69():5-23. PubMed ID: 31421264
[TBL] [Abstract][Full Text] [Related]
56. Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.
Rashdan S; Gerber DE
Transl Lung Cancer Res; 2019 Jun; 8(3):202-207. PubMed ID: 31367533
[No Abstract] [Full Text] [Related]
57. Clinical Response of Live-Attenuated,
Hassan R; Alley E; Kindler H; Antonia S; Jahan T; Honarmand S; Nair N; Whiting CC; Enstrom A; Lemmens E; Tsujikawa T; Kumar S; Choe G; Thomas A; McDougall K; Murphy AL; Jaffee E; Coussens LM; Brockstedt DG
Clin Cancer Res; 2019 Oct; 25(19):5787-5798. PubMed ID: 31263030
[TBL] [Abstract][Full Text] [Related]
58. The role of combination chemo-immunotherapy in advanced non-small cell lung cancer.
Rocco D; Della Gravara L; Battiloro C; Gridelli C
Expert Rev Anticancer Ther; 2019 Jul; 19(7):561-568. PubMed ID: 31188040
[No Abstract] [Full Text] [Related]
59. Interventions for smoking cessation in people diagnosed with lung cancer.
Zeng L; Yu X; Yu T; Xiao J; Huang Y
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD011751. PubMed ID: 31173336
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy for small cell lung cancer: mechanisms of resistance.
Hamilton G; Rath B
Expert Opin Biol Ther; 2019 May; 19(5):423-432. PubMed ID: 30855195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
